Revamping Health Management for Sustainable Development Goals: Insights from Kenya, Malawi, and Uganda

By HEOR Staff Writer

July 17, 2023

The potential of Primary Health Care (PHC) in achieving the Sustainable Development Goals (SDGs) is widely acknowledged. In Eastern and Southern Africa, governments have been progressively decentralising health decision-making, making health management a critical aspect of PHC performance. A study published by Oxford, conducted an in-depth political economy analysis in Kenya, Malawi, and Uganda, focusing on local decision-making environments and their impact on health management and governance practices. 

The study involved a comprehensive set of questions for key informants regarding health planning, budgeting, and implementation. These included understanding local processes and their deviations from established guidelines, identification of local health priorities, the impact of health system arrangements such as decentralisation and governance on health plans, and the dynamics of power relationships among the involved actors. The study also explored the processes for community engagement and gathered suggestions for improving the planning process.

 

Findings highlight several complex issues that need attention to strengthen health management and governance. These range from unfinished reforms under decentralisation, underfunded health plans, to counterproductive working environments for managers. 

Their recommendations aim to address these issues by focusing on managerial capacity, community engagement, coordination, and innovative financing. These small improvements can make the overall system more functional and effective. 

However, these challenges are complex and systemic, requiring leadership and engagement from government actors at multiple levels. The ongoing COVID-19 pandemic has further emphasised the need for resilient health systems and a crisis response mechanism.

Reference url

Recent Posts

Cemiplimab Cervical Cancer Access
Cemiplimab Cervical Cancer Access Navigating Treatment and Value

By João L. Carapinha

June 24, 2026

Cemiplimab Cervical Cancer Access has been endorsed by NICE for adults with recurrent or metastatic cervical cancer that has progressed after platinum-based chemotherapy, provided patients have not previously received immunotherapy. The final draft guidance confirms that this PD-1 inhibitor deliv...
Teplizumab Type 1 Diabetes
Recommendation for Teplizumab Type 1 Diabetes Routine Use

By João L. Carapinha

June 23, 2026

Teplizumab for Type 1 Diabetes now has a clear route to routine NHS use after NICE recommended the therapy for delaying progression from stage 2 to stage 3 disease in people aged 8 and older. The decision, dependent on a confidential commercial discount, offers families more time before insulin d...
USTR Germany Pharma Investigation
USTR Germany Pharma Investigation and its Impact on Global Drug Pricing

By João L. Carapinha

June 19, 2026

The USTR Germany Pharma Investigation has exposed how Germany’s pharmaceutical reimbursement policies force American patients to finance a disproportionately large share of worldwide drug research and development. By systematically suppressing prices below sustainable levels, these practices erod...